Terns Pharmaceuticals details 2023 clinical milestones; cash runway to 2026

Terns Pharmaceuticals, Inc.

Plan to initiate US Phase 1 trial for TERN-701 (CML) in H2 2023; top-line readouts 2024. Due to IRA, will not seek US approval for Ph+ ALL.
Phase 2a DUET trial of TERN-501 (NASH) expects enrollment completion Q1 2023, top-line data Q3 2023; first combo of THR-β and FXR agonist.
Obesity program TERN-601 (GLP-1 agonist) Phase 1 start H2 2023, top-line data in 2024; preclinical data to be published.
Cash runway extended to 2026: $293M adjusted cash includes $106M net from Dec 2022 equity offering; excludes potential collaborations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.